Surveillance of Pancreatic Health After Diabetes Diagnosis
NCT: NCT06803771 · RECRUITING
Brief Summary
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.
Frequently Asked Questions
What is Surveillance of Pancreatic Health After Diabetes Diagnosis?
Surveillance of Pancreatic Health After Diabetes Diagnosis is a clinical trial registered under NCT06803771. Current status: RECRUITING.
What is the status of NCT06803771?
The current status of NCT06803771 (Surveillance of Pancreatic Health After Diabetes Diagnosis) is: RECRUITING.
When did Surveillance of Pancreatic Health After Diabetes Diagnosis start?
Surveillance of Pancreatic Health After Diabetes Diagnosis started on 2025-05-21.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.